

Saturday, June 18
Yellow Hall
18.30-20.30

Working Group on Blood Pressure Monitoring

Welcome

E. O'Brien (*Dublin, Ireland*)

SESSION I: PREDICTING OUTCOME

Chairman: M. Myers (*Toronto, Canada*)

AASI: rationale and methodology

E. O'Brien (*Dublin, Ireland*)

E. Dolan (*Dublin, Ireland*)

AASI and outcome

J. Staessen (*Leuven, Belgium*),

Y. Li (*Shanghai, China*)

OvA: Further analyses of outcome

D.L. Clement (*Gent, Belgium*)

M. De Buyzere (*Gent, Belgium*)

ABPM v SBPM

P. de Leeuw (*Maastricht, Belgium*)

B. Kroon (*Maastricht, Belgium*)

Discussion

SESSION II: DETECTING HIDDEN PHENOMENA

Chairman: J. Redon (*Valencia, Spain*)

White coat & masked hypertension in children

G. Stergiou (*Athens, Greece*)

White coat hypertension in adults

P. Verdecchia (*Perugia, Italy*)

Masked hypertension in adults

P. Palatini (*Padua, Italy*), D. Longo (*Padua, Italy*)

Prevalence of masked and white coat hypertension

Y. Imai (*Sendai, Japan*)

White coat effect

T. Pickering (*New York, NY, USA*)

Prevalence of masked and white coat hypertension in elderly subjects

J.M. Mallion (*Grenoble, France*)

How to improve the assessment of 24 h blood pressure variability

G. Parati (*Milan, Italy*), G. Bilo (*Milan, Italy*)

Discussion

Close of Meeting

Monday, June 20
Yellow Hall
18.30-21.00

Working Group on Blood Pressure and Heart Rate Variability (EUROBAVAR)

Welcome.

An introduction to standards for spontaneous BRS assessment

G. Parati (*Milan, Italy*)

SESSION I: PHYSIOLOGICAL BACKGROUND

Chairman: **L. Quintin** (*Lyon, France*)

Baroreflex modulation of spontaneous BP and HR fluctuations. CNS, respiratory and chemoreflex influences on spontaneous baroreflex physiology

P. Martinka (*Berlin, Germany*)

C. Julien (*Lyon, France*)

B. Janssen (*Maastricht, The Netherlands*)

K. Narkiewicz (*Gdansk, Poland*)

P. Persson (*Berlin, Germany*)

SESSION II: STANDARDS OF MEASUREMENT

Chairman: **M. Di Rienzo** (*Milan, Italy*)

Requirements for cardiovascular signal recording. Baroreflex sensitivity based on central and peripheral pressures. Algorithmic recommendations for BRS assessment

J.-O. Fortrat (*Angers, France*)

M. Di Rienzo (*Milan, Italy*)

A. Cividjian (*Lyon, France*)

P. Castiglioni (*Milan, Italy*)

A. Porta (*Milan, Italy*)

SESSION III: PATHOPHYSIOLOGICAL RELEVANCE AND CLINICAL USE

Chairman: **G. Parati** (*Milan, Italy*)

Normal references values and predictors of BRS - Reproducibility of baroreflex gain - Clinical relevance of baroreflex sensitivity

P. Lantelme (*Lyon, France*)

M. Pagani (*Milan, Italy*)

M.T. La Rovere (*Montescano-PV, Italy*)

L. Quintin (*Lyon, France*)

G. Parati (*Milan, Italy*)

SESSION IV: RECENT EVIDENCE

Chairman: **J.-O. Fortrat** (*Angers, France*)

HRV in a population. New perspectives from a new approach

J.-C. Barthelemy (*St. Etienne, France*)

Angiotensin and HRV

J.-C. Le Mevel (*Brest, France*)

HRV and BPV in obese subjects. Humoral and metabolic correlates

A. Pathak (*Toulouse, France*)

Close of Meeting

Monday, June 20
Red Hall 2
18.30-20.30

Working Group on Integrated Approach to the High Risk Patient

Potential benefits of intervention on intermediate end-points

Chairman:

L.M. Ruilope (*Madrid, Spain*)

Left ventricular hypertrophy

M.L. Muiesan (*Brescia, Italy*)

Microalbuminuria

R. Pontremoli (*Genoa, Italy*)

Arterial compliance

S. Laurent (*Paris, France*)

Changes in small arteries

E. Agabiti Rosei (*Brescia, Italy*)

Tuesday, June 21
Red Hall 1
09.00-12.00

Working Group on Endothelin and Endothelial Factors

Chairmen:

A.C. Pessina (*Padua, Italy*)

A. Salvetti (*Pisa, Italy*)

Introductory remarks

A.C. Pessina (*Padua, Italy*)

Round table discussion:
**Proposals for a multicenter study in
endothelial function and dysfunction**
All members of the Working Group

Coffee break

Concluding remarks

A. Salvetti (*Pisa, Italy*)

*All members of the ESH and participants to the ESH Meeting are cordially invited to attend

Tuesday, June 21
Blue Hall
08.55-12.20

Working Group on Hypertension and the Kidney

Welcome

P.W. de Leeuw (*Maastricht, The Netherlands*)

Session I: Renal artery stenosis

Chairman: **A. Mimran** (*Montpellier, France*)

Renal artery stenosis: MRA or no MRA

A.A. Kroon (*Maastricht, The Netherlands*)

Renal artery stenosis: to stent or not to stent

M. Burnier (*Lausanne, Switzerland*)

Functional consequences of renal artery stenosis

P.W. de Leeuw (*Maastricht, The Netherlands*)

Coffee break

Session II: Renal failure and renal protection

Chairman: **M. Burnier** (*Lausanne, Switzerland*)

Aldosterone and the progression of renal failure

B.M.W. Schmidt (*Erlangen, Germany*),

R.E. Schmieder (*Erlangen, Germany*)

Target blood pressure for renoprotection

E. Ritz (*Heidelberg, Germany*)

Renal protection in diabetes

A. Mimran (*Montpellier, France*)

Closing remarks

L.M. Ruilope (*Madrid, Spain*)

Tuesday, June 21
Yellow Hall 1
09.00-12.00

Working Group on Vascular Structure and Function

Introduction and welcome

H.A.J. Struijker-Boudier (*Maastricht, The Netherlands*),

S. Laurent (*Paris, France*)

Synthesis and conclusion of the February 3 meeting

S. Laurent (*Paris, France*)

Toward an European compendium of normal and abnormal values: how to proceed?

J.A. Staessen (*Leuven, Belgium*)

Local arterial stiffness and pulse wave velocity: which parameters? Which diseases?

P. Boutouyrie (*Paris, France*)

Pulse wave analysis: which parameters? Which diseases?

J. Cockcroft (*Cardiff, UK*)

Updating of ongoing pharmacological trials

C. Giannattasio (*Milan, Italy*)

S. Thom (*London, UK*)

New developments on arterial parameters: the experience of the Eureka project

L. Van Bortel (*Gent, Belgium*)

Establishment of a Scientific Steering Committee

S. Laurent (*Paris, France*)

H.A.J. Struijker-Boudier (*Maastricht, The Netherlands*)

Conclusions

H.A.J. Struijker-Boudier (*Maastricht, The Netherlands*)

Tuesday, June 21
Yellow Hall 2
09.00-12.00

Working Group on Hypertension in Diabetes

Introduction and welcome

P. Nilsson (*Malmö, Sweden*)

R. Cífková (*Prague, Czech Republic*)

Pharmacological treatment of hypertension in pregnant diabetic subjects

S. Erdine (*Istanbul, Turkey*)

How to prevent microalbuminuria or its progression to overt proteinuria in diabetic patients?

H. Haller (*Hannover, Germany*)

PPAR-gamma agonism and blood pressure lowering

P. Sarafidis (*Thessaloniki, Greece*)

Coffee break

Treatment of hypertension in diabetes after ASCOT

B. Dahlöf (*Göteborg, Sweden*)

Updated ESH Newsletter on treatment of hypertension in type 2 diabetes

P.M. Nilsson (*Malmö, Sweden*)

Concluding remarks

R. Cífková (*Prague, Czech Republic*)

Tuesday, June 21
Yellow Hall 3
09.00-12.00

Working Group on Endocrine Hypertension

Opening

K. Pacak (*Bethesda, MD, USA*),

J. Lenders (*Nijmegen, The Netherlands*)

Mutations in the SDHB gene are associated with extra-adrenal and/or malignant pheochromocytomas (Results of the PGL.NET and COMETE networks)

A.P. Gimenez-Roqueplo (*Paris, France*)

Hereditary paraganglioma: an emerging link between Krebs cycle and hypoxic signaling

B. Baysal (*Pittsburg, PA, USA*)

Genetics and biology of pheo

M. Mannelli (*Florence, Italy*)

Pheochromocytoma: hypertension with high cardiovascular risk

J. Widimski (*Prague, Czech Republic*)

Coffee break

Follow-up of patients with malignant/recurrent pheochromocytoma or paraganglioma

P.F. Plouin (*Paris, France*)

Metabolic and cardiovascular consequences of hypercortisolism

F. Mantero (*Padua, Italy*)

Is the type of assay for measuring plasma renin relevant for the diagnosis of primary hyperaldosteronism?

J. Deinum (*Nijmegen, The Netherlands*)

Growth hormone excess and hypertension

E. Agabiti Rosei (*Brescia, Italy*)